Drug intelligence / Profile preview

DoriVac-102

Development stage: Preclinical
Lead developer: DoriNano
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

DoriVac-102 is an investigational nanoparticle cancer vaccine being developed by DoriNano for the treatment of high-grade serous ovarian cancer (HGSOC). The candidate is built upon the proprietary DoriVac (DNA Origami Vaccine) platform, which utilizes self-assembling DNA nanostructures to precisely control the spatial organization and stoichiometry of tumor-associated antigens and immunostimulatory adjuvants, such as CpG oligonucleotides. This nanoscale precision is designed to mimic the natural presentation of pathogens to the immune system, thereby enhancing uptake by dendritic cells and promoting a potent, targeted T-cell-mediated anti-tumor response. DoriVac-102 is currently in the preclinical stage of development.

Other names: DoriVac-102-DoriNano-nanoparticle cancer vaccine-High-Grade Serous Ovarian CancerDoriVac102-DoriNano-nanoparticle cancer vaccine-High-Grade Serous Ovarian CancerDoriVac 102-DoriNano-nanoparticle cancer vaccine-High-Grade Serous Ovarian Cancer

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on DoriVac-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DoriVac-102.

Explore the full profile